$2.25
1.81% yesterday
Nasdaq, Jun 26, 10:00 pm CET
ISIN
US45773H2013
Symbol
INO

Inovio Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Inovio Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
67%
Hold
33%

Inovio Pharmaceuticals, Inc. Price Target

Target Price $10.20
Price $2.25
Potential
Number of Estimates 6
6 Analysts have issued a price target Inovio Pharmaceuticals, Inc. 2026 . The average Inovio Pharmaceuticals, Inc. target price is $10.20. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 6 Analysts recommend Inovio Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Inovio Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Inovio Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 0.22 3.90
73.49% 1,673.64%
Net Margin -48,750.00% -1,963.65%
199.46% 95.97%

6 Analysts have issued a sales forecast Inovio Pharmaceuticals, Inc. 2025 . The average Inovio Pharmaceuticals, Inc. sales estimate is

$3.9m
Unlock
. This is
1,293.57% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$16.0m 5,596.43%
Unlock
, the lowest is
$63.7k 77.25%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $220k 73.49%
2025
$3.9m 1,673.64%
Unlock
2026
$20.4m 423.63%
Unlock
2027
$74.0m 262.33%
Unlock
2028
$150m 103.11%
Unlock
2029
$250m 66.55%
Unlock
2030
$286m 14.31%
Unlock
2031
$294m 2.84%
Unlock
2032
$290m 1.36%
Unlock

6 Inovio Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Inovio Pharmaceuticals, Inc. net profit estimate is

$-76.6m
Unlock
. This is
20.58% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-37.7m 60.89%
Unlock
, the lowest is
$-97.5m 1.09%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-107m 20.63%
2025
$-76.6m 28.56%
Unlock
2026
$-66.4m 13.36%
Unlock
2027
$-32.8m 50.53%
Unlock
2028
$18.9m 157.52%
Unlock
2029
$41.5m 119.59%
Unlock
2030
$58.2m 40.19%
Unlock
2031
$58.2m 0.00%
Unlock
2032
$64.8m 11.45%
Unlock

Net Margin

2024 -48,750.00% 199.46%
2025
-1,963.65% 95.97%
Unlock
2026
-324.87% 83.46%
Unlock
2027
-44.36% 86.35%
Unlock
2028
12.56% 128.31%
Unlock
2029
16.56% 31.85%
Unlock
2030
20.31% 22.64%
Unlock
2031
19.75% 2.76%
Unlock
2032
22.32% 13.01%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.95 -2.09
35.14% 47.09%
P/E negative
EV/Sales 3.63

6 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast for earnings per share. The average Inovio Pharmaceuticals, Inc. EPS is

$-2.09
Unlock
. This is
16.06% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.03 58.63%
Unlock
, the lowest is
$-2.66 6.83%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.95 35.14%
2025
$-2.09 47.09%
Unlock
2026
$-1.81 13.40%
Unlock
2027
$-0.90 50.28%
Unlock
2028
$0.52 157.78%
Unlock
2029
$1.13 117.31%
Unlock
2030
$1.59 40.71%
Unlock
2031
$1.59 0.00%
Unlock
2032
$1.77 11.32%
Unlock

P/E ratio

Current -0.90 40.13%
2025
-1.08 19.52%
Unlock
2026
-1.24 14.81%
Unlock
2027
-2.51 102.42%
Unlock
2028
4.37 274.10%
Unlock
2029
1.99 54.46%
Unlock
2030
1.42 28.64%
Unlock
2031
1.42 0.00%
Unlock
2032
1.27 10.56%
Unlock

Based on analysts' sales estimates for 2025, the Inovio Pharmaceuticals, Inc. stock is valued at an EV/Sales of

and an P/S ratio of
21.15
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 50.56 65.00%
2025
3.63 92.82%
Unlock
2026
0.69 80.90%
Unlock
2027
0.19 72.40%
Unlock
2028
0.09 50.76%
Unlock
2029
0.06 40.02%
Unlock
2030
0.05 12.39%
Unlock
2031
0.05 2.83%
Unlock
2032
0.05 1.46%
Unlock

P/S ratio

Current 294.71 1.23%
2025
21.15 92.82%
Unlock
2026
4.04 80.90%
Unlock
2027
1.11 72.40%
Unlock
2028
0.55 50.77%
Unlock
2029
0.33 39.96%
Unlock
2030
0.29 12.53%
Unlock
2031
0.28 2.74%
Unlock
2032
0.28 1.36%
Unlock

Current Inovio Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Oppenheimer
Locked
Locked
Locked May 14 2025
RBC Capital
Locked
Locked
Locked May 14 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 19 2025
RBC Capital
Locked
Locked
Locked Mar 19 2025
Citizens Capital Markets
Locked
Locked
Locked Mar 14 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 13 2025
JMP Securities
Locked
Locked
Locked Jan 10 2025
Analyst Rating Date
Locked
Oppenheimer:
Locked
Locked
May 14 2025
Locked
RBC Capital:
Locked
Locked
May 14 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 19 2025
Locked
RBC Capital:
Locked
Locked
Mar 19 2025
Locked
Citizens Capital Markets:
Locked
Locked
Mar 14 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 13 2025
Locked
JMP Securities:
Locked
Locked
Jan 10 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today